How Much Does DiHexa Cost in 2026?
DiHexa is a synthetic peptidomimetic derived from angiotensin IV, developed at Washington State University and studied for its potential pro-cognitive effects via hepatocyte growth factor (HGF) receptor signaling. It attracted early interest in the nootropic research community due to reported potency in animal synaptogenesis studies. In April 2026, the FDA removed DiHexa from the Category 2 503A bulk drug substances list, affecting compounding pharmacy access.
Current DiHexa Prices by Supplier
DiHexa is a peptidomimetic (not a standard linear peptide), which makes synthesis more complex. This is reflected in its pricing — typically higher per milligram than smaller conventional peptides.
| Supplier | Size | Price | Notes |
|---|---|---|---|
| Genetic Peptide Active Listing | 5mg (capsules) | $160.00 | ~$32/mg. Oral capsule form. COA provided. |
DiHexa is a specialty peptidomimetic with limited supply sources. Price sourced from publicly available listings, May 2026. Verify current pricing directly with each supplier before ordering.
What Is DiHexa?
DiHexa (chemical name: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a peptidomimetic compound — meaning it mimics the structure of a peptide but with chemical modifications that enhance its stability and oral bioavailability compared to standard peptides. It was developed by researchers at Washington State University as a derivative of angiotensin IV.
DiHexa works through a different mechanism than most nootropic compounds. Rather than directly modulating neurotransmitter systems (like acetylcholine or dopamine), DiHexa appears to potentiate hepatocyte growth factor (HGF) / MET receptor signaling — a pathway that plays important roles in synaptic plasticity, neurogenesis, and neuroprotection. Early animal studies reported effects that were described by the original researchers as extraordinarily potent at promoting new synapse formation in hippocampal models.
What Researchers Study DiHexa For
- Cognitive function and memory — Animal studies have examined DiHexa's effects on spatial memory tasks (Morris water maze), object recognition, and other cognitive measures, particularly in models of cognitive impairment.
- Neuroplasticity and synaptogenesis — Research has looked at DiHexa's apparent ability to promote new synaptic connections in hippocampal tissue, which the original research team suggested could be relevant to conditions like Alzheimer's disease.
- HGF/MET pathway activation — As the mechanism of action, HGF/MET signaling itself is a research topic, with implications for neuroprotection, neuroinflammation, and recovery from brain injury.
- Oral bioavailability research — Unlike most peptides that degrade in the digestive tract, DiHexa's peptidomimetic structure may confer greater oral stability, making it a subject of delivery mechanism research.
DiHexa and the April 2026 FDA Reclassification
DiHexa was included in the April 23, 2026 FDA removal of 12 peptides from the Category 2 503A bulk drug substances list. Prior to this, compounding pharmacies could prepare DiHexa for patients under physician oversight. This is no longer legally permitted for 503A pharmacies.
The July 2026 PCAC meeting offers an opportunity for the research and medical community to present additional clinical evidence. The evidence base for DiHexa is currently thin — a relatively small body of preclinical research without human trial data — which may make the case for reinstatement challenging without new data.
See the full FDA Peptide Reclassification 2026 guide for details.
Notable Research Suppliers (2026)
Genetic Peptide
What to Look for in a DiHexa Supplier
- Third-party COAs with correct MW — DiHexa has a specific molecular weight (~612 Da). Mass spectrometry confirmation alongside HPLC purity data (≥98%) is important for a peptidomimetic.
- Chemical characterization — Given DiHexa's non-standard structure, structural verification (NMR or equivalent) from a reputable supplier adds confidence.
- Named independent testing lab — All COA data should come from an external, independent laboratory.
- Lyophilized or crystalline form — DiHexa is typically supplied as a lyophilized powder or salt. Pre-dissolved formulations are less stable.
Frequently Asked Questions
How much does DiHexa cost?
DiHexa is priced at $160.00 for a 5mg capsule supply (approximately $32/mg) from Genetic Peptide as of May 2026. Its peptidomimetic structure makes synthesis more complex than standard research peptides, which is reflected in the premium pricing. DiHexa has fewer active suppliers than most other research peptides due to this synthesis complexity.
Is DiHexa the same as angiotensin IV?
No. DiHexa is derived from angiotensin IV but is a modified peptidomimetic, not the same molecule. The modifications (hexanoic acid cap, aminohexanoic amide tail) were specifically designed to improve stability and extend the half-life of the compound compared to the parent peptide angiotensin IV, which degrades quickly in biological systems.
Can DiHexa be taken orally in research settings?
DiHexa's peptidomimetic structure was partially designed with oral stability in mind. Some animal research has included oral administration routes. However, bioavailability data in humans does not exist, and oral research is still being characterized. This is one of the features that distinguishes DiHexa from conventional injectable-only research peptides.
How should DiHexa be stored?
Lyophilized DiHexa should be stored at −20°C for long-term stability. Once reconstituted for research use, store at 4°C and use within 2–4 weeks. Avoid exposure to light, heat, and repeated freeze-thaw cycles.
📬 Get a Free DiHexa Price Alert
Prices are actively updating post-reclassification. We'll notify you when verified pricing is available or when prices drop.